Impedimed Limited · ASX:IPD
Impedimed — Investor Presentation (September 2012)
16 slides from Impedimed's investor presentation, Sep 10, 2012
Slide 1: ASX Announcement – ImpediMed Company Presentation
ASX: IPD For personal use only 10 September 2012 ASX RELEASE ASX ANNOUNCEMENT – ImpediMed Company Presentation Brisbane, Australia - ImpediMed Limited (ASX: IPD) refers shareholders to the attached Company update presentation. Richard Carreon CEO ENDS For further information contact: Richard Carreon
Slide 2: Business Update
For personal use only Business Update Richard Carreon, President & CEO September 2012
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been produced by ImpediMed Limited (“ImpediMed”) only and may contain forward-looking statements that are based on management’s current expectations, beliefs and assumptions and are subject to a number of risks and uncertainties. The forward-loo
Slide 4: Relevant Experience – Richard Carreon
Relevant Experience – Richard Carreon For personal use only Responsible for commercialising 5 therapies and 1 Commercialisation diagnostic device (upon FDA approval) Worked closely with the physicians, societies, and Women’s Health advocacy groups involved in women’s health issues Involved with the
Slide 5: Key ImpediMed Business Attributes
Key ImpediMed Business Attributes For personal use only ‣ Bioimpedance Spectroscopy Technology - A growth platform ‣ First-mover advantage ‣ Sizable Market Opportunity ‣ Building evidence of strong health economic drivers ‣ Clinical Data – Over 50 peer reviewed journals, published abstracts, and man
Slide 6: Lymphoedema
Lymphoedema For personal use only “Lymphoedema – oedema that results from chronic lymphatic insufficiency – is a chronic debilitating disease that is frequently misdiagnosed, treated too late, or not treated at all” Source: Szuba, A., et al., The third circulation: radionuclide lymphoscintigraphy in
Slide 7: Background
Background For personal use only ‣ Current Measurements • Tape • Water displacement • Perometry ‣ Drawbacks • Difficult to replicate • No standardized cut-off • Not widely available in the patient care continuum • Not FDA cleared for lymphoedema assessment • May not detect subclinical lymphoedema 66
Slide 8: The Market
The Market For personal use only Incidence Opportunity Impact Upper 30% 1% to 47% ~$2 Billion Lower 70% over 5 years The incidence of lymphoedema after axillary Lower body lymphoedema is Estimated cost to the U.S. lymph node dissection ranges from 13- 47%1-5. After sentinel lymph node biopsy, estima
Slide 9: Product Platforms
Product Platforms For personal use only L-Dex ® U400 L-Dex ® UB500 FDA Cleared In development and not FDA cleared Provides a direct measure for extracellular Extends the direct measure capabilities to fluid (ECF) to aid in the clinical assessment aid in the clinical assessment and and monitoring of
Slide 10: How We Win
How We Win For personal use only Disciplined Accelerate Favorable Execution Adoption Reimbursement ‣ Focus, integrate, stage, and ‣ Refine physician/clinician and ‣ Secure local and regional execute an aggressive market patient programs to drive reimbursement while executing development strategy ado
Slide 11: Integrated Revenue Strategy
Integrated Revenue Strategy For personal use only Phase 1 - Expand Phase 2 - Adoption Sell key centers (multi center Train physicians/clinicians and sites, KOLs in single centers, patients, in key centers to HMOs, and ACOs in collect clinical evidence strategically important and cost savings data ge
Slide 12: Integrated Growth Strategy
Integrated Growth Strategy For personal use only ‣ Focus on key geographies that have high potential for expansion of existing customers and adding new customers ‣ Train key centers as reference sites ‣ Obtain payment for readings at local and regional payers ‣ Expand adoption Illustrative Only 1111
Slide 13: Health Maintenance Organization
Health Maintenance Organization For personal use only ‣ The new Kaiser Breast Cancer Survivorship Clinic has begun seeing patients from two local system hospitals ‣ Standardized L-Dex protocol is being implemented ‣ Lymphoedema screening part of electronic medical record for participating system hos
Slide 14: Multi Centers
Multi Centers For personal use only ‣ Operates 94 centers in 16 states ‣ Initial installation in 6 centers in 3 states ‣ Standing order L-Dex procedure for all breast cancer patients has been established ‣ Establishing procedural data base to further study utilisation of L-Dex and lymphoedema protoc
Slide 15: Key ImpediMed Business Attributes
Key ImpediMed Business Attributes For personal use only ‣ Bioimpedance Spectroscopy Technology - A growth platform ‣ First-mover advantage ‣ Sizable Market Opportunity ‣ Building evidence of strong health economic drivers ‣ Clinical Data – Over 50 peer reviewed journals, published abstracts, and man
Slide 16: For personal use only
For personal use only